Unicycive Therapeutics Inc (UNCY)
$4.77
$0.00 (0.00%)As on 18-Sep-2026 13:34EDT
Market cap
$145 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.7
-
Face value
--
-
Shares outstanding
27,393,027
6 Years Aggregate
CFO
$-43.11 Mln
EBITDA
$-51.39 Mln
Net Profit
$-64.05 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Unicycive Therapeutics Inc (UNCY)
| -17.3 | -14.4 | -32.3 | 18.1 | -11.7 | -29.9 | -- |
|
BSE Sensex
| -12.3 | -4.4 | -3.7 | -10.2 | 3.1 | 4.7 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Unicycive Therapeutics Inc (UNCY)
| -27.3 | -8.4 | 60.7 | -73.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Unicycive Therapeutics Inc (UNCY)
|
4.8 | 144.9 | 0.0 | -35.2 | -- | -84.4 | -- | 2.8 |
| 66.8 | 11,702.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 25.1 | |
| 68.3 | 10,255.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 58.1 | 13,905.5 | 2,435.9 | 860.6 | 31.0 | 43 | 17.6 | 7.5 | |
| 111.8 | 12,167.0 | 1,663.7 | 413.6 | 36.3 | 430 | 31.4 | 84.6 | |
| 336.3 | 10,270.8 | 440.5 | 241.5 | 33.4 | 18.7 | 43.3 | 7.6 | |
| 529.3 | 12,348.9 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.5 | |
| 610.8 | 16,398.7 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.5 | 37.5 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 | |
| 142.7 | 9,588.5 | 282.0 | 82.9 | -28.6 | 11.4 | 142.5 | 11.2 |
Shareholding Pattern
View DetailsAbout Unicycive Therapeutics Inc (UNCY)
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate... binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California. Read more
-
Founder, Chairman, CEO & President
Dr. Shalabh K. Gupta M.D., MPA
-
Founder, Chairman, CEO & President
Dr. Shalabh K. Gupta M.D., MPA
-
Headquarters
Mountain View, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Unicycive Therapeutics Inc (UNCY)
What is the current share price of Unicycive Therapeutics Inc (UNCY) Today?
The share price of Unicycive Therapeutics Inc (UNCY) is $4.77 (NASDAQ) as of 18-Sep-2026 13:34 EDT. Unicycive Therapeutics Inc (UNCY) has given a return of -11.66% in the last 3 years.
What is the current PB & PE ratio of Unicycive Therapeutics Inc (UNCY)?
Since, TTM earnings of Unicycive Therapeutics Inc (UNCY) is negative, P/E ratio is not available.
The P/B ratio of Unicycive Therapeutics Inc (UNCY) is 2.78 times as on 11-Sep-2026, a 43 discount to its peers’ median range of 4.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.32 |
3.80 |
2024 |
-0.17 |
0.83 |
2023 |
-0.10 |
-0.79 |
2022 |
-0.05 |
-1.77 |
2021 |
-0.29 |
0.19 |
What is the 52 Week High and Low of Unicycive Therapeutics Inc (UNCY)?
The 52-week high and low of Unicycive Therapeutics Inc (UNCY) are Rs 8.74 and Rs 3.72 as of 19-Sep-2026.
What is the market cap of Unicycive Therapeutics Inc (UNCY)?
Unicycive Therapeutics Inc (UNCY) has a market capitalisation of $ 145 Mln as on 11-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Unicycive Therapeutics Inc (UNCY)?
Before investing in Unicycive Therapeutics Inc (UNCY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.